Summary
No overall score for this company yet.
What speaks for it
- It earns 58 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Is it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $42.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.